Mumbai 20th May 2025: Innova Captab Limited is a leading integrated pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter and financial year ending March 31st, 2025.

Key Highlights

Q4 FY25 vs Q4 FY24

• Revenue from Operations registered robust growth of20%, reaching₹ 314.7 crores vs ₹ 262.6 crores in Q4 FY24, driven by strong performance across all business areas
• Overall EBITDA registered stellar growth of17%, reaching₹ 51.1 crores vs ₹ 43.8 crores in Q4 FY24. EBITDA margins were 16.2%
• PAT rose by3%year-over-year to ₹ 29.6 crores after absorbing the impact of depreciation and finance costs associated with Kathua, Jammu plant (commercialized in January 2025). PAT margins stood at 9.4%

FY25 vs FY24

• Revenue from Operations grew15%to ₹ 1,243.7 crores vs ₹ 1,081.3 crores in FY24, led by volume growth across business areas
• EBITDA registered robust growth of19%to ₹ 198.2 crores vs ₹ 166.9 crores in FY24. EBITDA margin increased by 50 basis points to 15.9%
• PAT witnessed strong growth of36%to ₹ 128.3 crores vs ₹ 94.3 crores in FY24, driven by higher EBITDA and reduced finance costs. PAT margins improved by 160 basis points to 10.3%

Commenting on the results, Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited said “We ended the year on a strong note, with all business areas performing in line with expectations. Strategic decisions taken over recent years are now delivering clear, measurable results—reflected in both our financial and operational performance. This momentum underscores the strength of our business model and the disciplined execution by our teams. We remain focused on our core priorities—growth, innovation, and customer centricity—despite a dynamic and evolving market environment.

Operationally, we deepened our CDMO partnerships, broadened our product portfolio, expanded further in global markets, and strengthened our domestic reach. The commissioning of our Kathua, Jammu facility is a major milestone, enabling scaled production of new products and dosage forms—fueling our next growth phase.

All these enabled us to deliver stellar performance, and we closed the year at ₹ 1,243.7 crores, up 15% from last year. Profitability also improved with PAT increasing by 36% to ₹ 128.3 crores.

These achievements reaffirm our long-term strategy. With sharper focus, enhanced capacity, and strong execution, we are well-positioned to drive sustainable growth and create lasting value.”